AKRO Akero Therapeutics, Inc.

19.210.52 (+2.76%)
IEX real time price: 11:55:26 AM

Quote

Previous Close
-
Day Range
-
52 Week Range
$16.06-$30.30
Volume
19,161
Avg Volume
138,197
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$548.41M
Enterprise Value (EV)
$457.73M
PE Ratio
-
EV/EBITDA
-33.22
Price/Sales
-
Price/Book
7.13
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$13.78M
EPS, ttm
-$5.11
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
11/27/2019 (43 days)
Debt to Equity
-
Debt
-
Cash
$75.98M
Net Debt
-

Performance

Beta
-0.80
200 Day Moving Avg
$22.43
50 Day Moving Avg
$23.45
52 Week Change
2.02%
YTD Change
4.77%
1 Month Change
-1.84%
3 Month Change
-9.93%
6 Month Change
2.02%
1 Year Change
2.02%
2 Year Change
2.02%
5 Year Change
2.02%

Share Count

Shares Outstanding
28.6M
Float
8.5M
Restricted Shares
20.1M
Restricted Shares, %
70.28%

Akero Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Major

CEO: Andrew Cheng

Website: http://www.akerotx.com

Description: Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Employees: 8